A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Study to Evaluate the Efficacy and Safety of VCT220 in Participants With Hypertension and Obesity or Overweight
Latest Information Update: 02 Feb 2026
At a glance
- Drugs VCT 220 (Primary)
- Indications Hypertension; Obesity
- Focus Therapeutic Use
- Sponsors Vincentage Pharma
Most Recent Events
- 02 Feb 2026 New trial record